Non-vitamin K antagonist oral anticoagulants with amiodarone, P-glycoprotein inhibitors, or polypharmacy in patients with atrial fibrillation

Systematic review and meta-analysis

In Soo Kim, Hyun Jung Kim, Hee Tae Yu, Tae Hoon Kim, Jae Sun Uhm, Jong Youn Kim, Boyoung Joung, Moon Hyoung Lee, huinam pak

Research output: Contribution to journalArticle

Abstract

Background: Amiodarone, which inhibits CYP2C9 and P-glycoprotein, is commonly prescribed with non-vitamin K antagonist oral anticoagulants (NOACs) and polypharmacy in high-risk atrial fibrillation (AF) patients. We studied efficacy and safety of NOACs in AF patients receiving amiodarone, P-glycoprotein inhibitor, or polypharmacy. Methods: After a systematic database search (Medline, EMBASE, CENTRAL, SCOPUS, and Web of Science), four phase-III randomized trials comparing NOACs and warfarin in “with/without amiodarone,” “with/without P-glycoprotein inhibitors,” or “with/without multiple (≥5, polypharmacy) concomitant drugs” subgroups were included. The outcomes were pooled using a random-effects model to determine the relative risks (RRs) for stroke/systemic thromboembolism (SSTE), major bleeding (MB), intracranial hemorrhage (ICH), and all-cause mortality. Results: Among patients taking amiodarone, superiority of NOACs over warfarin in non-amiodarone users disappeared in terms of SSTE (p = 0.11), MB (p = 0.95), ICH (p = 0.26), and mortality (p = 0.32). No safety benefit (MB) of NOACs compared to warfarin was shown in patients taking P-glycoprotein inhibitors (p = 0.47), but SSTE prevention was still superior with NOACs compared to warfarin in the same patient group [RR = 0.78 (0.61–0.99), p = 0.04, I 2 = 11%]. In AF patients with polypharmacy, NOACs showed a lower risk of SSTE [RR = 0.82 (0.71–0.96), p = 0.01, I 2 = 0%] and mortality [RR = 0.91 (0.83–0.99), p = 0.04, I 2 = 0%], but not MB (p = 0.81) compared to warfarin. Conclusions: NOACs were equivalent to warfarin among AF patients with concomitant amiodarone use in terms of efficacy, safety, and mortality. There was no safety benefit of NOACs over warfarin in patients using polypharmacy or P-glycoprotein inhibitors. Systematic review registration: The protocol of this meta-analysis was registered on PROSPERO under CRD42018104808 (https://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42018104808).

Original languageEnglish
Pages (from-to)515-521
Number of pages7
JournalJournal of Cardiology
Volume73
Issue number6
DOIs
Publication statusPublished - 2019 Jun 1

Fingerprint

Polypharmacy
Amiodarone
P-Glycoprotein
Anticoagulants
Atrial Fibrillation
Meta-Analysis
Warfarin
Thromboembolism
Stroke
Hemorrhage
Safety
Mortality
Intracranial Hemorrhages
Viperidae
Databases

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Kim, In Soo ; Kim, Hyun Jung ; Yu, Hee Tae ; Kim, Tae Hoon ; Uhm, Jae Sun ; Kim, Jong Youn ; Joung, Boyoung ; Lee, Moon Hyoung ; pak, huinam. / Non-vitamin K antagonist oral anticoagulants with amiodarone, P-glycoprotein inhibitors, or polypharmacy in patients with atrial fibrillation : Systematic review and meta-analysis. In: Journal of Cardiology. 2019 ; Vol. 73, No. 6. pp. 515-521.
@article{29f42cbc33ea4611a3c50f665a3fba98,
title = "Non-vitamin K antagonist oral anticoagulants with amiodarone, P-glycoprotein inhibitors, or polypharmacy in patients with atrial fibrillation: Systematic review and meta-analysis",
abstract = "Background: Amiodarone, which inhibits CYP2C9 and P-glycoprotein, is commonly prescribed with non-vitamin K antagonist oral anticoagulants (NOACs) and polypharmacy in high-risk atrial fibrillation (AF) patients. We studied efficacy and safety of NOACs in AF patients receiving amiodarone, P-glycoprotein inhibitor, or polypharmacy. Methods: After a systematic database search (Medline, EMBASE, CENTRAL, SCOPUS, and Web of Science), four phase-III randomized trials comparing NOACs and warfarin in “with/without amiodarone,” “with/without P-glycoprotein inhibitors,” or “with/without multiple (≥5, polypharmacy) concomitant drugs” subgroups were included. The outcomes were pooled using a random-effects model to determine the relative risks (RRs) for stroke/systemic thromboembolism (SSTE), major bleeding (MB), intracranial hemorrhage (ICH), and all-cause mortality. Results: Among patients taking amiodarone, superiority of NOACs over warfarin in non-amiodarone users disappeared in terms of SSTE (p = 0.11), MB (p = 0.95), ICH (p = 0.26), and mortality (p = 0.32). No safety benefit (MB) of NOACs compared to warfarin was shown in patients taking P-glycoprotein inhibitors (p = 0.47), but SSTE prevention was still superior with NOACs compared to warfarin in the same patient group [RR = 0.78 (0.61–0.99), p = 0.04, I 2 = 11{\%}]. In AF patients with polypharmacy, NOACs showed a lower risk of SSTE [RR = 0.82 (0.71–0.96), p = 0.01, I 2 = 0{\%}] and mortality [RR = 0.91 (0.83–0.99), p = 0.04, I 2 = 0{\%}], but not MB (p = 0.81) compared to warfarin. Conclusions: NOACs were equivalent to warfarin among AF patients with concomitant amiodarone use in terms of efficacy, safety, and mortality. There was no safety benefit of NOACs over warfarin in patients using polypharmacy or P-glycoprotein inhibitors. Systematic review registration: The protocol of this meta-analysis was registered on PROSPERO under CRD42018104808 (https://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42018104808).",
author = "Kim, {In Soo} and Kim, {Hyun Jung} and Yu, {Hee Tae} and Kim, {Tae Hoon} and Uhm, {Jae Sun} and Kim, {Jong Youn} and Boyoung Joung and Lee, {Moon Hyoung} and huinam pak",
year = "2019",
month = "6",
day = "1",
doi = "10.1016/j.jjcc.2018.12.018",
language = "English",
volume = "73",
pages = "515--521",
journal = "Journal of cardiography. Supplement",
issn = "0914-5087",
publisher = "Japanese College of Cardiology (Nippon-Sinzobyo-Gakkai)",
number = "6",

}

Non-vitamin K antagonist oral anticoagulants with amiodarone, P-glycoprotein inhibitors, or polypharmacy in patients with atrial fibrillation : Systematic review and meta-analysis. / Kim, In Soo; Kim, Hyun Jung; Yu, Hee Tae; Kim, Tae Hoon; Uhm, Jae Sun; Kim, Jong Youn; Joung, Boyoung; Lee, Moon Hyoung; pak, huinam.

In: Journal of Cardiology, Vol. 73, No. 6, 01.06.2019, p. 515-521.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Non-vitamin K antagonist oral anticoagulants with amiodarone, P-glycoprotein inhibitors, or polypharmacy in patients with atrial fibrillation

T2 - Systematic review and meta-analysis

AU - Kim, In Soo

AU - Kim, Hyun Jung

AU - Yu, Hee Tae

AU - Kim, Tae Hoon

AU - Uhm, Jae Sun

AU - Kim, Jong Youn

AU - Joung, Boyoung

AU - Lee, Moon Hyoung

AU - pak, huinam

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Background: Amiodarone, which inhibits CYP2C9 and P-glycoprotein, is commonly prescribed with non-vitamin K antagonist oral anticoagulants (NOACs) and polypharmacy in high-risk atrial fibrillation (AF) patients. We studied efficacy and safety of NOACs in AF patients receiving amiodarone, P-glycoprotein inhibitor, or polypharmacy. Methods: After a systematic database search (Medline, EMBASE, CENTRAL, SCOPUS, and Web of Science), four phase-III randomized trials comparing NOACs and warfarin in “with/without amiodarone,” “with/without P-glycoprotein inhibitors,” or “with/without multiple (≥5, polypharmacy) concomitant drugs” subgroups were included. The outcomes were pooled using a random-effects model to determine the relative risks (RRs) for stroke/systemic thromboembolism (SSTE), major bleeding (MB), intracranial hemorrhage (ICH), and all-cause mortality. Results: Among patients taking amiodarone, superiority of NOACs over warfarin in non-amiodarone users disappeared in terms of SSTE (p = 0.11), MB (p = 0.95), ICH (p = 0.26), and mortality (p = 0.32). No safety benefit (MB) of NOACs compared to warfarin was shown in patients taking P-glycoprotein inhibitors (p = 0.47), but SSTE prevention was still superior with NOACs compared to warfarin in the same patient group [RR = 0.78 (0.61–0.99), p = 0.04, I 2 = 11%]. In AF patients with polypharmacy, NOACs showed a lower risk of SSTE [RR = 0.82 (0.71–0.96), p = 0.01, I 2 = 0%] and mortality [RR = 0.91 (0.83–0.99), p = 0.04, I 2 = 0%], but not MB (p = 0.81) compared to warfarin. Conclusions: NOACs were equivalent to warfarin among AF patients with concomitant amiodarone use in terms of efficacy, safety, and mortality. There was no safety benefit of NOACs over warfarin in patients using polypharmacy or P-glycoprotein inhibitors. Systematic review registration: The protocol of this meta-analysis was registered on PROSPERO under CRD42018104808 (https://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42018104808).

AB - Background: Amiodarone, which inhibits CYP2C9 and P-glycoprotein, is commonly prescribed with non-vitamin K antagonist oral anticoagulants (NOACs) and polypharmacy in high-risk atrial fibrillation (AF) patients. We studied efficacy and safety of NOACs in AF patients receiving amiodarone, P-glycoprotein inhibitor, or polypharmacy. Methods: After a systematic database search (Medline, EMBASE, CENTRAL, SCOPUS, and Web of Science), four phase-III randomized trials comparing NOACs and warfarin in “with/without amiodarone,” “with/without P-glycoprotein inhibitors,” or “with/without multiple (≥5, polypharmacy) concomitant drugs” subgroups were included. The outcomes were pooled using a random-effects model to determine the relative risks (RRs) for stroke/systemic thromboembolism (SSTE), major bleeding (MB), intracranial hemorrhage (ICH), and all-cause mortality. Results: Among patients taking amiodarone, superiority of NOACs over warfarin in non-amiodarone users disappeared in terms of SSTE (p = 0.11), MB (p = 0.95), ICH (p = 0.26), and mortality (p = 0.32). No safety benefit (MB) of NOACs compared to warfarin was shown in patients taking P-glycoprotein inhibitors (p = 0.47), but SSTE prevention was still superior with NOACs compared to warfarin in the same patient group [RR = 0.78 (0.61–0.99), p = 0.04, I 2 = 11%]. In AF patients with polypharmacy, NOACs showed a lower risk of SSTE [RR = 0.82 (0.71–0.96), p = 0.01, I 2 = 0%] and mortality [RR = 0.91 (0.83–0.99), p = 0.04, I 2 = 0%], but not MB (p = 0.81) compared to warfarin. Conclusions: NOACs were equivalent to warfarin among AF patients with concomitant amiodarone use in terms of efficacy, safety, and mortality. There was no safety benefit of NOACs over warfarin in patients using polypharmacy or P-glycoprotein inhibitors. Systematic review registration: The protocol of this meta-analysis was registered on PROSPERO under CRD42018104808 (https://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42018104808).

UR - http://www.scopus.com/inward/record.url?scp=85061298968&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061298968&partnerID=8YFLogxK

U2 - 10.1016/j.jjcc.2018.12.018

DO - 10.1016/j.jjcc.2018.12.018

M3 - Article

VL - 73

SP - 515

EP - 521

JO - Journal of cardiography. Supplement

JF - Journal of cardiography. Supplement

SN - 0914-5087

IS - 6

ER -